University Medical Center Groningen
Groningen, 9700RB, Netherlands
NCT Number: NCT02497664
Neo-adjuvant chemoradiotherapy (neo-CRT) is increasingly applied in the curative treatment of esophageal cancer, with the aim to downstage the tumor, to increase the rate of radical resections, and consequently to improve the survival rates. Due to improved survival, it will become increasingly important to minimize the radiation-induced toxicity among long-term survivors.
In the management of locally advanced non small cell lung cancer (NSCLC), radiotherapy is the standard treatment modality. However, the dose that can be safely applied to the tumour is limited by the risk of cardiac and pulmonary complications, which even led to decreased survival in a randomised study, when a higher tumor dose was administered [1].
Radiation induced pulmonary and cardiac toxicity are the most important late side effects after thoracic radiotherapy [2-4].
The aim of this study is to reduce the radiation dose of heart (and lungs) in order to reduce the toxicity risk.
In recent years, the active breathing control (ABC) technique has been introduced in the radiotherapy for left sided breast cancer patients, to minimize the radiation dose to the heart. These patients are irradiated in the inspiration phase, in which the distance between the heart and the breast is largest, while the lungs extend.
Breath hold might also be beneficial for radiotherapy of esophageal and lung tumors. For these patients the expiratory phase might theoretically be more beneficial to reduce the heart dose. However, the inspiration phase might be better for the dose to the lungs, which consequently allows cardiac dose reduction.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Groningen, 9700RB, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At 6 weeks after start of radiation therapy
Time frame: At 6 weeks after start of radiation therapy
Time frame: At 6 weeks after start of radiation therapy
Time frame: At 6 weeks after start of radiation therapy
Time frame: At 6 weeks after start of radiation therapy
V5, V10, V20, V30, V40, V50, V60
University Medical Center Groningen
Other
Acronym: ABC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05708950
Adnexal Diseases, Breast Cancer
Santa Monica, California, United States
View Trial DetailsNCT05787522
Breast Cancer, Breast Diseases
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT04825834
Bladder Cancer, Colonic Diseases
Homewood, Alabama, United States
View Trial DetailsNCT05697198
Adnexal Diseases, Breast Cancer
Fort Payne, Alabama, United States
View Trial Details